Gregory S. Day

8.1k total citations · 2 hit papers
119 papers, 3.6k citations indexed

About

Gregory S. Day is a scholar working on Neurology, Psychiatry and Mental health and Physiology. According to data from OpenAlex, Gregory S. Day has authored 119 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Neurology, 37 papers in Psychiatry and Mental health and 29 papers in Physiology. Recurrent topics in Gregory S. Day's work include Autoimmune Neurological Disorders and Treatments (48 papers), Alzheimer's disease research and treatments (29 papers) and Dementia and Cognitive Impairment Research (29 papers). Gregory S. Day is often cited by papers focused on Autoimmune Neurological Disorders and Treatments (48 papers), Alzheimer's disease research and treatments (29 papers) and Dementia and Cognitive Impairment Research (29 papers). Gregory S. Day collaborates with scholars based in United States, Canada and Germany. Gregory S. Day's co-authors include Alexander Rae‐Grant, Gary Gronseth, Thomas S.D. Getchius, Melissa J. Armstrong, Ronald C. Petersen, Tamara Pringsheim, Mary Ganguli, Daniel Marson, David Gloss and Oscar L. López and has published in prestigious journals such as Cell, Journal of Neuroscience and Neurology.

In The Last Decade

Gregory S. Day

109 papers receiving 3.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Practice guideline update summary: Mild cognitive impairment [RETIRED]

2017 1.4k citations Ronald C. Petersen, Gregory S. Day et al. Neurology profile →
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis

2018 395 citations Gregory S. Day et al. Neurology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Gregory S. Day	1.2k	1.2k	657	498	441	119	3.6k
Roberto Monastero	1.6k 1.3×	734 0.6×	1.0k 1.5×	253 0.5×	445 1.0×	113	3.7k
L. Amaducci	907 0.7×	1.3k 1.1×	770 1.2×	302 0.6×	399 0.9×	98	3.8k
Rita Moretti	829 0.7×	765 0.6×	539 0.8×	611 1.2×	335 0.8×	118	3.2k
Alfredo Costa	1.3k 1.1×	438 0.4×	1.1k 1.7×	544 1.1×	240 0.5×	168	4.1k
Jennifer M. Nicholas	853 0.7×	509 0.4×	797 1.2×	651 1.3×	674 1.5×	98	3.1k
Knut Waterloo	585 0.5×	1.3k 1.1×	370 0.6×	643 1.3×	414 0.9×	109	4.9k
Jordi A. Matías‐Guiu	946 0.8×	968 0.8×	497 0.8×	487 1.0×	687 1.6×	191	3.1k
Alexander Rae‐Grant	1.0k 0.8×	649 0.5×	392 0.6×	1.1k 2.3×	308 0.7×	56	3.5k
Peter K. Panegyres	649 0.5×	775 0.7×	631 1.0×	243 0.5×	263 0.6×	106	2.8k
Peter W. Schofield	947 0.8×	503 0.4×	655 1.0×	159 0.3×	424 1.0×	94	3.3k

Countries citing papers authored by Gregory S. Day

Since Specialization

Citations

This map shows the geographic impact of Gregory S. Day's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory S. Day with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory S. Day more than expected).

Fields of papers citing papers by Gregory S. Day

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory S. Day. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory S. Day. The network helps show where Gregory S. Day may publish in the future.

Co-authorship network of co-authors of Gregory S. Day

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory S. Day. A scholar is included among the top collaborators of Gregory S. Day based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory S. Day. Gregory S. Day is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith, Tammy, Ka‐Ho Wong, Lisa K. Peterson, et al.. (2025). An updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: Analysis, equipoise, and the urgent need for evidence over anecdote. Journal of Neuroimmunology. 405. 578651–578651. 3 indexed citations

Day, Gregory S., et al.. (2025). Uremic Toxins, CKD, and Cognitive Dysfunction. Journal of the American Society of Nephrology. 36(6). 1208–1226. 2 indexed citations

McCarter, Stuart J., Vijay K. Ramanan, Hugo Botha, et al.. (2025). Longitudinal Evolution of Posterior Cortical Atrophy. Neurology. 104(9). e213559–e213559.

Abboud, Hesham, Stacey Clardy, Divyanshu Dubey, et al.. (2025). The Clinical Trial Landscape in Autoimmune Encephalitis. Neurology. 104(8). e213487–e213487. 4 indexed citations

Grant, Eleanor, Andrew G. Murchison, Sophie Binks, et al.. (2024). Magnetic Resonance Imaging Characteristics of LGI1-Antibody and CASPR2-Antibody Encephalitis. JAMA Neurology. 81(5). 525–525. 8 indexed citations

Trani, Jean‐Francois, Samantha Murphy, Monique Williams, et al.. (2024). Recruiting a prospective community cohort to study Alzheimer's disease and structural and social determinants of health among adults racialized as Black: The ARCHES cohort. Alzheimer s & Dementia Translational Research & Clinical Interventions. 10(2). e12473–e12473. 4 indexed citations

Tipton, Philip W., et al.. (2024). Diagnostic Performance and Clinical Applications of a Commercial Alpha-synuclein Seed Amplification Assay in a Tertiary Care Memory Clinic (S1.010). Neurology. 102(7_supplement_1). 1 indexed citations

Selwa, Linda M., Brenda Banwell, Meeryo Choe, et al.. (2024). The Neurologist's Role in Promoting Brain Health. Neurology. 104(1). e210226–e210226. 3 indexed citations

Tipton, Philip W., Yuka A. Martens, Steven Dunham, et al.. (2023). Improving Early Recognition of Treatment‐Responsive Causes of Rapidly Progressive Dementia: The STAM₃P Score. Annals of Neurology. 95(2). 237–248. 6 indexed citations

10.

Tipton, Philip W., Alexandra I. Soto‐Beasley, Gregory S. Day, et al.. (2023). CWH43 Variants Are Associated With Disease Risk and Clinical Phenotypic Measures in Patients With Normal Pressure Hydrocephalus. Neurology Genetics. 9(5). e200086–e200086. 7 indexed citations

11.

Ramanan, Vijay K., Jonathan Graff‐Radford, Jeremy A. Syrjanen, et al.. (2023). Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort. Neurology. 101(14). e1402–e1411. 45 indexed citations

12.

Kommaddi, Reddy Peera, Aditi Verma, Graciela Muñiz‐Terrera, et al.. (2023). Sex difference in evolution of cognitive decline: studies on mouse model and the Dominantly Inherited Alzheimer Network cohort. Translational Psychiatry. 13(1). 123–123. 11 indexed citations

13.

Millar, Peter R, Brian A. Gordon, Patrick H. Luckett, et al.. (2023). Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study. eLife. 12. 31 indexed citations

14.

Brier, Matthew R., et al.. (2023). Real‐time quaking‐induced conversion assays for prions: Applying a sensitive but imperfect test in clinical practice. European Journal of Neurology. 30(7). 1854–1860. 4 indexed citations

15.

Xu, Ying, Randall J. Bateman, William S. Brooks, et al.. (2023). Higher systolic blood pressure in early‐mid adulthood is associated with poorer cognitive performance in those with a dominantly inherited Alzheimer's disease mutation but not in non‐carriers. Results from the DIAN study. Alzheimer s & Dementia. 19(11). 4999–5009. 2 indexed citations

16.

Nissim, Nicole R., Christian Lachner, Ganesh M. Babulal, et al.. (2023). Age-Specific Barriers and Facilitators to Research Participation Amongst African Americans in Observational Studies of Memory and Aging. Journal of Racial and Ethnic Health Disparities. 11(5). 2796–2805. 3 indexed citations

17.

Li, Zonghua, Michael G. Heckman, Takahisa Kanekiyo, et al.. (2022). Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment. Neurology. 98(20). e2036–e2045. 10 indexed citations

18.

Wong, Ka‐Ho, Gregory S. Day, Maarten J. Titulaer, et al.. (2022). The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis. Neurology. 99(23_Supplement_2). 1 indexed citations

19.

LaMontagne, Pamela, Matthew F. Glasser, Randall J. Bateman, et al.. (2021). Regional age-related atrophy after screening for preclinical alzheimer disease. Neurobiology of Aging. 109. 43–51. 9 indexed citations

20.

Klein, Christopher J., Elia Sechi, Eva Alden, et al.. (2021). LGI1 antibody encephalitis: acute treatment comparisons and outcome. Journal of Neurology Neurosurgery & Psychiatry. 93(3). 309–315. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact